2seventy Bio, Inc. operates as cell and gene therapy company. It concentrates on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.
Clinical Trials
1
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Completed
1
100.0%
No approval data available
- Bristol Myers Squibb's subsidiary 2seventy bio has filed a patent infringement lawsuit against Johnson & Johnson and Legend Biotech at the Unified Patent Court, targeting their CAR-T cell therapy Carvykti. - The dispute centers on European patent EP 3 689 383, which protects a chimeric antigen receptor targeting B-cell maturation antigens, with both companies' therapies treating multiple myeloma. - This marks the first pharmaceutical case for the Brussels local division of the UPC and represents the growing trend of biotech patent disputes at the European court. - Parallel revocation proceedings have been initiated in the UK, while the patent remains under opposition at the European Patent Office, indicating a multi-jurisdictional battle over this critical cancer therapy technology.
- ResearchAndMarkets.com has released a comprehensive report analyzing licensing deals in biotechnology from 2020 to 2025, providing insights into deal trends and structures. - The report covers hundreds of companies including major players like AbbVie, ACADIA Pharmaceuticals, and emerging biotech firms across various therapeutic areas and technology types. - Key features include financial terms analysis covering upfront payments, milestones, and royalties, plus access to actual contract documents for due diligence purposes. - The analysis enables benchmarking of transaction values and identification of the most active dealmakers in the biotechnology licensing landscape.
- The European Commission has granted expanded approval to Bristol Myers Squibb's CAR T cell therapy Breyanzi (lisocabtagene maraleucel) for treating adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. - In the Phase II TRANSCEND FL trial, Breyanzi demonstrated impressive efficacy with a 97.1% overall response rate and 94.2% complete response rate in third-line and beyond treatment settings. - The approval extends across all European Union member states plus Norway, Liechtenstein, and Iceland, addressing significant unmet needs for follicular lymphoma patients with limited treatment options.
- Bristol Myers Squibb has agreed to acquire 2seventy bio for $286 million, ending the profit-sharing arrangement for the BCMA-targeted CAR-T therapy Abecma used in multiple myeloma treatment. - The acquisition represents an 88% premium over 2seventy's closing share price but marks the end of a challenging journey for the cell therapy company, which was spun out from bluebird bio in 2021. - BMS's strategic move aligns with its cost-cutting initiatives aimed at saving $3.5 billion through 2027, as the company faces patent expirations for key products including Opdivo, Yervoy, and Eliquis.
- Bristol Myers Squibb has acquired 2seventy Bio for $102 million net, just weeks after Bluebird Bio, 2seventy's parent company, was sold for a mere $30 million, highlighting significant valuation challenges in the gene therapy sector. - The low acquisition prices for both companies underscore the broader business challenges facing gene therapy developers, despite creating treatments that deliver life-changing value to patients. - Despite recent setbacks and commercial hurdles related to complex manufacturing and high pricing, biopharmaceutical companies continue to invest in gene therapy research, indicating ongoing confidence in the field's scientific potential.
- The first quarter of 2025 witnessed significant biotech partnership activity, with Eli Lilly, AstraZeneca, and Novo Nordisk emerging as top collaborators in deals worth billions across small molecules, antibodies, and RNA therapeutics. - February 2025 featured notable acquisitions including Novartis's $2.15 billion buyout of Anthos Therapeutics, while March saw AstraZeneca acquire Belgian biotech EsoBiotec and Bristol Myers Squibb purchase 2seventy bio for $286 million. - Obesity therapeutics gained significant traction in March 2025, with AbbVie entering the field through a $350 million upfront deal with Gubra for an amylin analog, while Roche partnered with Zealand Pharma on petrelintide in a deal worth up to $5.25 billion.
- Bristol Myers Squibb and 2seventy bio halted enrollment in the Phase 3 KarMMa-9 trial evaluating Abecma (idecabtagene vicleucel) plus lenalidomide maintenance versus lenalidomide alone in newly diagnosed multiple myeloma (NDMM) patients. - The decision was driven by challenges in patient enrollment due to the evolving treatment landscape, where more intense induction therapies result in fewer eligible patients for the trial. - Advances in induction therapies now lead to complete responses or better in over 70% of NDMM patients post-transplant, reducing the eligible population for KarMMa-9, which aimed for patients with suboptimal responses. - Both companies will collaborate with investigators to determine the next steps for patients already participating in the KarMMa-9 study, while reaffirming their commitment to Abecma in multiple myeloma treatment.
• 2Seventy Bio has stopped enrolling patients in the Phase 3 KarMMa-9 study evaluating Abecma in newly diagnosed multiple myeloma patients with suboptimal responses to stem cell transplants. • The decision aims to save $80 million and help 2Seventy Bio achieve financial breakeven next year, following a $27 million operating loss in the second quarter. • The discontinuation was influenced by the improved treatment landscape for newly diagnosed multiple myeloma, resulting in fewer eligible patients for the study. • Abecma, co-developed with Bristol Myers Squibb, remains available for later-line treatment of multiple myeloma, with 2Seventy Bio projecting continued revenue growth.
